|Day Low/High||1.10 / 1.13|
|52 Wk Low/High||0.76 / 10.87|
Harwood Feffer LLP ( www.hfesq.
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court, Western District of Texas on behalf of purchasers of Pain Therapeutics, Inc.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Pain Therapeutics, Inc.
Headline of release should read: Bronstein, Gewirtz & Grossman, LLC Investigates Pain Therapeutics, Inc.
Pain Therapeutics (Nasdaq:PTIE) has been downgraded by TheStreet Ratings from from a hold to sell.
Pain Therapeutics (Nasdaq:PTIE) is trading at unusually high volume Tuesday with 2.7 million shares changing hands. It is currently at 4.2 times its average daily volume and trading up 8 cents (+2%).
Pain Therapeutics (Nasdaq:PTIE) is trading at unusually high volume Friday with 3.1 million shares changing hands. It is currently at 6.4 times its average daily volume and trading down $3.89 (-42.1%).
U.S. stock futures are pointing to a largely flat open as the market weighs better-than-expected May durable goods orders and ongoing efforts to address Greece's debt crisis.
Shares of Pain Therapeutics and Pfizer were falling in premarket trading Friday as U.S. regulators rejected a tamper-resistant painkiller from the companies.
Pfizer and Pain Therapeutics have been trying to get Remoxy, a tamper-resistant painkiller, approved for three years.
Pfizer (NYSE: PFE) and Pain Therapeutics, Inc. (NASDAQ: PTIE) announced that a Complete Response Letter was received from the U.
The Pfizer/Acura painkiller Oxecta consists of the narcotic oxycodone combined with ingredients to make the drug resistant to tampering and abuse.
Acura, Pain Therapeutics and Fibrocell deal with FDA approval decisions while Curis presents new cancer drug data.
Pain Therapeutics (Nasdaq:PTIE) hit a new 52-week high Thursday as it is currently trading at $10.38, above its previous 52-week high of $10.37 with 220,760 shares traded as of 11:02 a.m. ET. Average volume has been 425,100 shares over the past 30 days.
Pain Therapeutics (Nasdaq:PTIE) is trading at unusually high volume Tuesday with 1.6 million shares changing hands. It is currently at four times its average daily volume and trading up 45 cents (+4.7%).
Pain Therapeutics (Nasdaq:PTIE) has been upgraded by TheStreet Ratings from a sell to hold.
Shareholders Receive $2.00 Cash Per Share
Non-Dilutive Funding for Cancer and Nervous System Drug Development
Painkillers are in the biotech spotlight Tuesday, as King Pharmaceuticals sells itself to Pfizer and tiny pain medicine developer Pain Therapeutics benefits by extension.
Pain Therapeutics and Acura Pharmaceuticals will partner with Pfizer once the King Pharma acquisition closes.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.